课程文献中心 更多>>

关键词： Synthesis   selective   phthalocyanine   Fe3   UV-visible  

摘要： In this study, first 3-(1,1-diphenylethoxy) propionic acid was obtained from the reaction of 1,1-diphenylethanol and 3-chloropropionic acid. Bis(3-(1,1-diphenylethoxy) propanoate) silicon phthalocyanine was obtained from the reaction of 3-(1,1-diphenylethoxy) propionic acid with SiPcCl₂. The newly prepared compounds were characterized by ¹H NMR, FT-IR, mass spectrometry and UV-vis spectroscopy. The singlet oxygen quantum yield for silicon phthalocyanine, which has the potential to be a photosensitizer, was determined as 0.13 by chemical method. Finally, metal ion selectivity of bis(3-(1,1-diphenylethoxy) propanoate) silicon phthalocyanine was determined by UV absorption spectroscopy. A total of 11 metal ions (Mg²⁺, Mn²⁺, Na⁺, Ni²⁺, Zn²⁺, Fe³⁺, Ba²⁺, Cd²⁺, Cu²⁺, Co²⁺, and Ag⁺) were used for testing. Of these metal ions, only the Fe³⁺ ion was selectively determined.

关键词： 银杏叶提取物注射液   药物性肝损伤   肝功能异常   转氨酶升高   药品不良反应  

摘要： 目的 探讨银杏叶提取物注射液引起的药物性肝损伤,为临床安全用药提供参考。方法 分析1例特发性耳聋患者使用银杏叶提取物注射液改善循环致药物性肝损伤的病例,结合国内外文献讨论不良反应发生机制、临床表现和治疗等。结果 患者使用银杏叶提取物注射液后发生药物性肝损伤,存在合理时间关联性,经停药及降酶保肝后肝功能恢复正常。结论 临床应警惕银杏叶提取物注射液对肝功能影响的风险,用药过程应定期进行肝功能的监测,并做好不良反应的对症治疗。

关键词： Genomics   immune checkpoint inhibitors   immunotherapy   mismatch repair deficiency   pembrolizumab   prostate cancer   tumor mutational burden  

摘要： IntroductionA growing number of malignancies have shown favorable responses to immune checkpoint inhibitors (ICI), most commonly anti-PD-(L)1 antibodies. However, prostate cancer has been associated with mostly unfavorable responses to ICI. This review discusses various trials related to PD-(L)1 inhibitors in prostate *** coveredWe wrote a review article based upon content and practice expertise supplemented with review of the literature. The focus was on PD-1 or PD-L1 inhibitors in prostate *** opinionClinical trials with PD-(L)1 inhibitors in patients with prostate cancer administered alone or in combination with other therapies do not appear to have significant benefit in unselected patients, whether part of initial systemic therapy or after the development of hormone resistance. However, there may be benefits in selected tumors harboring mutations with microsatellite instability high/mismatch repair deficiency (MSI-H/dMMR) and, to a lesser extent, high tumor mutational burden (TMB-H). While only a small percentage of prostate tumors have these mutations (MSI-H/dMMR: 3%) and (TMB-H: 4.5%), panel genomic testing can help identify subsets of patient populations who may benefit from PD-(L)1 inhibitors in addition to other molecularly selected agents.